ReviewCancers2023
Emerging Targeted Therapies in Advanced Non-Small-Cell Lung Cancer.
Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 3 syntheses or guidelines pooled it, 61 citations in OpenAlex.
- Effects of Kang'ai injection combined with chemotherapy on immune function in advanced non-small cell lung cancer: a meta-analysis.Frontiers in pharmacology · 2026Pooled it
- The safety and efficacy of binimetinib for lung cancer: a systematic review.BMC pulmonary medicine · 2024Pooled it
- Emerging biomarkers for non-invasive diagnosis and treatment of cancer: a systematic review.Frontiers in oncology · 2024Pooled it
- Quantitative [Molecular imaging and biology · 2026Trial
- Advances in Understanding How RhoB Regulates Akt Inhibition Efficacy in NSCLC.Current cancer drug targets · 2026Article
- EGFR: New Insights on Its Activation and Mutation in Tumor and Tumor Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Advancements in lung cancer: molecular insights, innovative therapies, and future prospects.Medical oncology (Northwood, London, England) · 2025Review
- Validation of a rapid biomarker assay for lung cancer using the IntelliPlex panel.Scientific reports · 2025Article
- Prediction for cardiac and pulmonary toxicity in a multicentric cohort of advanced stage NSCLC patients using sub-regions of the heart.Clinical and translational radiation oncology · 2025Article
- Repression of ZNFX1 by LncRNA ZFAS1 mediates tobacco-induced pulmonary carcinogenesis.Cellular & molecular biology letters · 2025Article
- Acetyl-CoA synthesis in the skin is a key determinant of systemic lipid homeostasis.Cell reports · 2025Article
- Epidemiological, pathological, and molecular characteristics of lung cancer in Casablanca, Morocco: a retrospective study.The Pan African medical journal · 2025Article
- Real-world treatment and retreatment patterns and outcomes in patients with advanced or metastatic non-small cell lung cancer following nivolumab monotherapy in second line or later in France: an I-O Optimise analysis.Frontiers in oncology · 2025Article
- Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy.Frontiers in immunology · 2025Review
- Review
- Article
- TheJournal of clinical medicine · 2024Review
- Emerging Targets in Non-Small Cell Lung Cancer.International journal of molecular sciences · 2024Review
- Exceptional long term response to crizotinib in ROS 1-postive advanced non small cell lung cancer.Respirology case reports · 2024Article
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions.Journal of clinical medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer remains the leading cause of cancer-related mortality worldwide. Non-small-cell lung cancer (NSCLC) is the most common type and is still incurable for most patients at the advanced stage. Targeted therapy is an effective treatment that has significantly improved survival in NSCLC patients with actionable mutations. However, therapy resistance occurs widely among patients leading to disease progression. In addition, many oncogenic driver mutations in NSCLC still lack targeted agents. New drugs are being developed and tested in clinical trials to overcome these challenges. This review aims to summarize emerging targeted therapy that have been conducted or initiated through first-in-human clinical trials in the past year.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.